Skip to Main content Skip to Navigation
Journal articles

Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity

Abstract : The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug–drug interactions, based on available evidence.
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03243144
Contributor : Isabelle Combe <>
Submitted on : Tuesday, June 1, 2021 - 9:12:27 AM
Last modification on : Wednesday, June 9, 2021 - 3:46:50 PM
Long-term archiving on: : Thursday, September 2, 2021 - 6:12:30 PM

File

mdr.2020.0232.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

Citation

Guillaume Hache, Jean Marc Rolain, Philippe Gautret, Jean-Claude Deharo, Philippe Brouqui, et al.. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microbial Drug Resistance, Mary Ann Liebert, 2021, 27 (3), pp.281-290. ⟨10.1089/mdr.2020.0232⟩. ⟨hal-03243144⟩

Share

Metrics

Record views

85

Files downloads

106